Printer Friendly

TARGETED GENETICS APPOINTS DIRECTOR OF CORPORATE DEVELOPMENT

 SEATTLE, April 1 /PRNewswire/ -- Targeted Genetics Corp. (TGC) announced today the appointment of Jon M. Case as director of Corporate Development.
 Case joins TGC from Centocor Inc., where he was director, Business Development. He combines his experience at Centocor with two years experience as an analyst for the venture capital group of First Boston Corp., where he focused on the evaluation of investment opportunities in biotechnology companies.
 "Case has experience in developing strategic alliances, in- licensing critical patents and cross-licensing technology," said H. Stewart Parker, TGC president and chief executive officer. "His knowledge of technology transfer will help guide the company at a most exciting time in its history."
 Case received his master of business admini (AUTM).
 Targeted Genetics Corp. is a leader in the development of integrated gene therapy treatments for acquired and inherited diseases. The company has begun its first Phase I trial, a gene therapy-based treatment for HIV infection.
 -0- 4/1/93
 /CONTACT: H. Stewart Parker, president and CEO, or Alberta L. Garvin, of Targeted Genetics, 206-623-7612/


CO: Targeted Genetics Corp. ST: Washington IN: MTC SU: PER

BP-LS -- SE004 -- 1851 04/01/93 08:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1993
Words:190
Previous Article:WATSCO, INC. DECLARES REGULAR CASH DIVIDENDS
Next Article:THE SOFTWARE TOOLWORKS APPOINTS JAMES P. MASLYN AS CHIEF FINANCIAL OFFICER
Topics:


Related Articles
TARGETED GENETICS NAMES BRUCE H. DEVENS DIRECTOR OF IMMUNOLOGY
Targeted Genetics Begins Second Phase I Clinical Trial of E1A Tumor Suppressor Gene Product
Targeted Genetics Reduces Long-Term Cash Obligations Through Conversion of Debt Into Equity.
Targeted Genetics Receives $4.8 Million in Equity Funding From Biogen.
Targeted Genetics Announces Todd E. Simpson to Step Down as Chief Financial Officer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters